BDBM289840 2-(Piperazin-1-yl)ethyl (4-(((2S)-1-(6-chloro-2-oxo-1,2-dihydrospiro[benzo[d][1,3]oxazine-4,3′-pyrrolidin]-1′-yl)-1-oxo-3-phenylpropan-2-yl)carbamoyl)phenyl)carbamate 2 trifluoroacetic acid salt::US10093683, Example 190
SMILES: Clc1ccc2NC(=O)OC3(CCN(C3)C(=O)[C@H](Cc3ccccc3)NC(=O)c3ccc(NC(=O)OCCN4CCNCC4)cc3)c2c1
InChI Key: InChIKey=RHRGDHLCMVVARN-MIXNXMPVSA-N
Data: 1 KI
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Coagulation factor XI (Homo sapiens (Human)) | BDBM289840 (2-(Piperazin-1-yl)ethyl (4-(((2S)-1-(6-chloro-2-ox...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 76.7 | -9.70 | n/a | n/a | n/a | n/a | n/a | 7.4 | 25 |
Merck Sharp & Dohme Corp. US Patent | Assay Description The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine... | US Patent US10093683 (2018) BindingDB Entry DOI: 10.7270/Q2RR2197 | |||||||||||
More data for this Ligand-Target Pair |